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Blood lipid concentrations are heritable risk factors associated with atherosclerosis and cardiovascular diseases. Lipid traits exhibit
considerable variation among populations of distinct ancestral origin as well as between individuals within a population. We performed
association analyses to identify genetic loci influencing lipid concentrations in African American and Hispanic American women in the
Women’s Health Initiative SNP Health Association Resource. We validated one African-specific high-density lipoprotein cholesterol
locus at CD36 as well as 14 known lipid loci that have been previously implicated in studies of European populations. Moreover, we
demonstrate striking similarities in genetic architecture (loci influencing the trait, direction and magnitude of genetic effects, and
proportions of phenotypic variation explained) of lipid traits across populations. In particular, we found that a disproportionate fraction
of lipid variation in African Americans and Hispanic Americans can be attributed to genomic loci exhibiting statistical evidence of
association in Europeans, even though the precise genes and variants remain unknown. At the same time, we found substantial allelic
heterogeneity within shared loci, characterized both by population-specific rare variants and variants shared among multiple
populations that occur at disparate frequencies. The allelic heterogeneity emphasizes the importance of including diverse populations
in future genetic association studies of complex traits such as lipids; furthermore, the overlap in lipid loci across populations of diverse
ancestral origin argues that additional knowledge can be gleaned from multiple populations.Introduction
Plasma concentrations of lipoproteins (low-density lipopro-
tein [LDL] cholesterol, high-density lipoprotein [HDL]
cholesterol, and triglycerides [TG] are heritable risk factors
for atherosclerosis and cardiovascular diseases (CVDs).1,2
These lipid concentrations vary substantially between
individuals as well as between populations.3 For example,
mean TG levels are highest among Hispanic American
populations; despite their higher CVD mortality, African
Americans tend to have higher HDL levels and lower TG
levels compared to whites.4–7 The heritability estimates of
blood lipids vary across studies and by population but are
consistently high: 40%–80% for both LDL and HDL and
30%–50% for TG.8–10 A recent meta-analysis of more than
100,000 individuals of European ancestry identified 95 loci
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transferrable,’’ in the sense that they show statistical associ-
ation and consistent direction of genetic effects in non-
European populations.3,11,12 Specifically, of the 36 LDL
loci, 44 HDL loci, and 30 TG loci examined in African
American participants, 33, 37, and 24 loci, respectively,
showed the same direction of association as in the European
cohorts; even higher ‘‘replication’’ rates were observed in
EastAsians, SouthAsians, andHispanics, suggestinga shared
genetic contribution to lipid variability among human pop-
ulations. However, our understanding of the ethnically
shared and distinct components of the genetic architecture
that underlie blood lipid concentrations is incomplete.Non-
replication could arise as a result of ethnic-specific causal
variants, different linkage disequilibrium (LD) patterns sur-
rounding the same causal variants, interaction effects with
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power. Furthermore, the genetic architecture underlying a
trait depends not only on the direction and magnitude of
genetic effects, but also on factors such as frequencies of
the risk variants. In other words, replication of variants
across populations does not automatically imply that these
variants constitute a substantial genetic component that
explains phenotype variation in all populations.
Characterizing the shared and distinct genetic compo-
nents that underlie complex traits among human popula-
tions has significant public health impact. Such an under-
standing regarding lipids levels can provide valuable
insights on the genetic contribution to ethnic health dis-
parities related to atherosclerosis and CVD across different
ethnicities. However, a genome-wide assessment of the
relative contribution of panethnic and population-specific
genetic components to any complex trait is analytically
challenging because our knowledge of the genetic architec-
ture within each population is limited. Here we present a
series of genome-wide analyses that consider various as-
pects of the genetic architecture of blood lipid levels, using
genotype and phenotype data from the Women’s Health
Initiative SNP Health Association Resource (WHI-SHARe),
which includes 8,153 African American (AA) and 3,587
Hispanic American (HA) participants. By applying a mixed
effects model that makes use of the full reference GWAS
(instead of just the top SNPs), we demonstrate that a large
overlapping genetic component influences individual vari-
ation of lipid levels across these populations, including
many loci that do not reach genome-wide significance level
in any population to date. At the same time, genotype asso-
ciation and admixture mapping analyses reveal important
population-specific lipid loci and variants. Our findings
argue that an effective approach for elucidating the genetic
architecture of complex traits is to combine evidence across
multiple populations. The analytic approach we use is
applicable to studies of other heritable complex traits.Material and Methods
Our analytic approach consists of three components. (1) A discov-
ery GWAS in a cohort of 8,153 WHI-SHARe AA samples and 3,587
HA samples. Validation analysis of variants not previously impli-
cated in a large EuropeanGWASwas performed in an independent
cohort of 7,138 AAs in the Candidate Gene Association Resource
(CARe). (2) Genome-wide assessment of transethnic overlap in
the genetic architecture underlying lipid variation was performed
with the WHI-SHARe AA and HA cohorts by examining statistical
significance, allelic effect, and proportion of variance explained by
subsets of the genome. (3) Characterization of genetic variation
that could account for population-level lipid differences by admix-
ture mapping in WHI-SHARe AAs and conditional analyses in
regions showing admixture signal (i.e., association between local
ancestry and trait).
Study Subjects
TheWHI is a U.S.-wide study focusing on commonhealth issues in
postmenopausal women. A total of 161,808 postmenopausal
women aged 50–79 years old were recruited, including 12,151The Amself-identified AAs and 5,469 self-identified HAs. Fasting blood
samples were collected at the baseline clinic visit by venipuncture.
Clinical information was collected by self-report and physical ex-
amination. All participants provided written informed consent as
approved by local Human Subjects Committees. Details of the
study design and cohort characteristics have been previously
described.13 An independent cohort of 7,138 AA participants
from the NHLBI Candidate-gene Association Resource (CARe)
Study was used to validate those SNP-trait associations identified
in WHI, which have not been reported in previous GWASs.11
Genotyping QC and Biomarker Measurement
Genotyping and QC
A cohort of 8,515 self-identified AA and 3,642 self-identified HA
participants from WHI, who had consented to genetic research,
were selected for WHI SHARe (n ¼ 12,157) and genotyped on
the Affymetrix 6.0 array. Genotype quality control criteria
included call rate, concordance rates for blinded and unblinded
duplicates, and sex discrepancy. Furthermore, individuals whose
genetic ancestries differ from self-reported ethnicities and one
individual from each close relative pair were excluded. In total,
11,740 individuals passed all genotype and sample QC criteria
(8,153 AA, 3,587 HA).14,15 Details of the QC procedures have
been described in previous WHI-SHARe studies.16,17 Sample sizes
for each stage of the study are displayed in Figure S1 available
online; demographic and lipid trait variables are summarized in
Table S1.
Lipid Measurements
HDL, LDL, and TG measurements were performed at the Univer-
sity of Minnesota by standard biochemical methods on the Roche
Modular P Chemistry analyzer (Roche Diagnostics): HDL was
measured in serum by the HDL-C plus third generation direct
method; TG was measured in serum by Triglyceride GB reagent,
and total cholesterol (TC) was measured in serum by a cholesterol
oxidase method. The accuracy and precision of the lipid assays
were regularly monitored with the CDC/NHLBI Lipid Standardiza-
tion Program to control for any potential drift over time. LDL was
calculated in serum specimens having a TG value < 400 mg/dl
according to the formula of Friedewald et al.18 Based on the
LDL-lowering effects of statins, we estimated the pretreatment
LDL value for individuals on lipid-lowering medication by
dividing treated LDL values by 0.75. All analyses described here
are based on analyzing the pretreatment LDL, although the results
are largely consistent when treated LDL values were analyzed. For
all association analyses, LDL values greater than 300mg/dl and TG
values greater than 650 md/dl were excluded. TG values were
log-transformed. HDL values were also log-transformed to better
satisfy the normality assumption for the linear and linear mixed
effect models, although post hoc analyses indicated that the trans-
formed and untransformed trait values yielded qualitatively
similar results, and in particular the identical set of genome-wide
significant loci.
Genotype Imputation
Imputed genotypes were examined in regions where at least one
genotyped SNP achieved a p < 106 and in regions showing
ancestry association in WHI AAs (p < 7 3 106). GWAS data in
the WHI AAs were prephased via MaCH, with options ‘‘–states
200’’ and ‘‘–rounds 50.’’19 The imputation reference panel was
derived from the 2012-02-14 release of the 1000 Genomes Project,
which included 246 Africans/African Americans, 379 Europeans,
181 Americans, and 286 Asians, using minimac with default para-
meter settings.20 We note that genome-wide imputation to 1000erican Journal of Human Genetics 92, 904–916, June 6, 2013 905
Genomes Project data is in fact available for WHI-SHARe. How-
ever, we chose not to test all imputed markers at the beginning
of the study based on a power consideration. The rationale is
that, for untyped risk variants with common frequencies, with
high probability, there would be a typed variant in moderate LD
in the vicinity reaching the relaxed threshold of p < 106. Addi-
tionally, this relaxed threshold can identify regions harboring
untyped rare variants, which are well tagged by a SNP on the array.
On the other hand, for regions harboring very rare variants that
are not tagged by any markers on the array, our sample size is
probably underpowered even if we tested the imputed genotype.
For this reason, we did not expect an exhaustive scan of all
imputed SNPs to be fruitful.Population Structure and Ancestry Estimation
Population Structure and Genome-level Ancestry
Principal component analysis (PCA) was performed for AAs and
HAs combined, using Eigenstrat21 at 178,101 markers that were
in common between our samples and the reference panels. We
also determined individual ancestral proportions by using Frappe
from 656,852 autosomal markers.22 For both of these calculations
we included 475 publicly available samples from ancestral popula-
tions (YRI and CEU from HapMap and East Asian and Native
Americans from the Human Genome Diversity Project).23
Local Ancestry Estimation
For each AA individual in the sample, locus-specific ancestry
(probabilities of whether an individual has 0, 1, or 2 alleles of
African ancestry at each locus) was estimated with program
SABERþ, an extension of the SABER algorithm.24 In brief, SABERþ
uses a graphical model approach to adaptively capture local haplo-
type structure within each ancestral population, and therebymore
accurately accounts for background linkage disequilibrium (LD). In
the current analysis, phased haplotype data from the HapMap3
CEU and YRI individuals were augmented as the reference
panels. In simulation studies, SABERþ has an error rate of less
than 2%, similar in accuracy to another commonly used method,
HapMix.25 Based on analysis of simulated and real AA genotypes,
the correlation between local-ancestry estimates produced by the
two methods is greater than 0.98 (N.A.J., unpublished data).GWAS Analysis
The overall GWAS strategy was as follows: we initially tested gen-
otyped SNPs inWHI AAs and HAs separately, with a ¼ 53 108 as
the threshold for genome-wide significance. In regions showing
suggestive evidence (at least one SNP with p < 106), imputed
genotypes were tested. To validate SNPs not previously associated
with lipid traits, we combined results from WHI AAs and CARe
AAs by using the programMETAL to perform sample-size weighted
meta-analysis.26 Association analysis in CARe used individual-
level genotype data and corrected for both PC1 and subcohort
membership. Genome-wide association (GWA) analysis was per-
formed under an additive genetic model using linear regression
adjusted for covariates and implemented in PLINK v.1.05.14
Analyses were conducted separately for AAs and HAs. To correct
for population stratification, the genome-wide European ancestry
proportions, which have a correlation of 0.99 with PC1, were
adjusted as covariates for AAs (PC2–PC10 showed no evidence of
association with any of the lipid traits). For HAs, the first four prin-
cipal components were adjusted as covariates (PC5–PC10 showed
no evidence of association with any of the lipid traits). Age, age2,
BMI, and smoking history were included as covariates for all lipid906 The American Journal of Human Genetics 92, 904–916, June 6, 2traits; additionally, fasting status was adjusted for LDL. The same
regression model was used to test the imputed allelic dosage at
each SNP, via MACH2QTL.19 The same threshold of 5 3 108
was used to declare genome-wide statistical significance for the
imputed genotypes, although we note that the significant regions
identified remained the same when a more stringent threshold of
2.5 3 108 was adopted.27Comparison of p Values and Genetic Effects between
Populations
We characterized the shared genetic architecture between
Europeans, AAs, and HAs by enrichment in statistical significance
(p values), correlation in estimated genetic effects, and the propor-
tions of variance explained by subsets of genomes. To delineate
the enrichment in statistical significance, we asked whether
SNPs showing suggestive evidence in Europeans (defined by
p< 105) tend to have small p values in AAs and HAs. The p values
in Europeans were taken from one of the largest lipid meta-
analysis to date.11 The p values for WHI AAs and HAs were
obtained from GWAS based on the single-marker additive model.
To compare genetic effects across populations, we again defined
candidate lipid-associated SNPs based on the p values in the
European GWAS (p < 105) and computed correlation coefficients
between the estimates in WHI AAs and HAs. Because all WHI
participants were genotyped with the same platform and all lipid
biomarkers were measured in a consistent manner, this analysis
avoids potential artifacts resulting from nonoverlapping SNPs,
allele flipping, and assay batch effects. Furthermore, because the
SNPs were chosen based on the p values in a GWAS whose partic-
ipants do not overlap with WHI, the estimated genetic effects in
AAs and HAs do not suffer from the typical bias due to selecting
the most significant SNPs (i.e., winner’s curse).28Estimation of Phenotypic Variance Explained by
Subsets of Genomes
We developed a method, termed population overlap in genetic
architecture (POGA), which tests the hypothesis that loci identi-
fied in one population explain a large proportion of the pheno-
typic variance in other populations. POGA is an extension of the
mixed effects model of a polygenic trait, introduced by Yang and
Visscher.29 Under this approach, we prioritized the genomes into
regions based on association evidence in Europeans and estimated
the phenotypic variance explained in AAs and HAs, using a mixed
effects model. We reasoned that if the genetic architecture over-
laps between populations, loci showing the strongest evidence
of association in one population would account for a dispropor-
tionate amount of phenotypic variation in another population.
POGA Algorithm
For each SNP genotyped in WHI, we assigned a priority score
(denoted by um) as the smallest p values within a 20 kb neighbor-
hood based on the European GWAS.11 We then grouped the
genome into 22 nested subsets, such that the first subset included
regions around SNPs that reached genome-wide significance in the
European GWAS (p < 5 3 108); the second subset included SNPs
with the top 1% priority scores; the third and subsequent subsets
incrementally included the 5%, 10%, . 100% of the markers
according to um. For each subset s¼ 1,.,22, we computed the pro-
portions of phenotypic variance explained with program GCTA
(v.1.02) and the AI-REML algorithm.30 The model is:
Yi ¼ aþ bQi þGsi þHsi þ εi;013
where Q are the fixed effect covariates (age and PCs) andGsi andH
s
i
are the random effects representing the genetic effects resulting
from markers included and excluded by set s respectively. The
inclusion of Hs in the model is necessary because markers in set
s can be in LD with flanking regions not in the set, and thus a
model that includes Gs alone tends to overestimate the variance
explained just by the genomic regions.
Genetic Relationship Matrix
In a standard application of GCTA, a genetic relationship matrix
(GRM) is computed as the covariance matrix of the standardized





gim˛ð0;1;2Þ represents the original genotype and pm represents
the allele frequencies.We have previously shown that relationship
coefficients estimated this way can be biased in an admixed pop-
ulation, and we have developed a reap estimator, which does not
suffer from such bias.31 In brief, the reap estimator standardizes
the genotype by an ‘‘admixture-adjusted’’ allele frequency:




where pim is the expected allele
frequencies given the individual’s genome-wide ancestry propor-
tions. For a given subset of markers, s, we computed the GRM by
using the reap estimator, for markers included in the subset (Gs)
and not included in the subset (Hs), and supplied these two
GRM into GCTA. For each subset, denote the proportions of vari-
ance attributed to Gsi as h
2
s . As an informal test of significance, we
compared the estimated h2s with a simple null model, under which
we expect that the phenotypic variance explained by a randomly
selected region is proportional to its coverage of the genome. Thus,
a set of regions that includes x% of the genome would explain
h2x% of the phenotypic variance, where h2 is the variance ex-
plained by the entire genome.
A Scenario with No Overlap in Genetic Architecture
To verify that the expected h2s , for a set of randomly selected re-
gions, is proportional to the proportion of the genome included,
we performed the following permutation experiment. First, the
European p value list was permuted in a way that largely preserves
the correlation structure between neighboring SNPs. The p values
were sorted by chromosome and base pair location. The 22 auto-
somes were concatenated, circularized, and then cut at a random
location. The resulting list of p values was then mapped to the
original SNP positions, starting with the p-term of chromosome
1 and ending with the last SNP position on chromosome 22.
This permuted list of p values were then used as if they were
p values from a European GWAS study, and the genomes were
regrouped based on these permuted p values. GCTA analyses
were repeated and h2s estimated for these randomly partitioned
genomes. This permutation procedure was performed for each
HDL, LDL, and TG p value list and used to estimate the proportion
of LDL variance explained.
Admixture Mapping
With the estimated local ancestry, we performed an admixture
mapping analysis in AAs to detect variants present at different fre-
quencies among the European and African ancestral populations.
In this analysis, we regressed lipid levels on locus-specific ancestry,
adjusting for the same covariates as in the GWAS. The critical value
for genome-wide significance level of admixture mapping is sub-
stantially lower than for the genotype test, because the recent
admixing history gives rise to extensive correlation in local
ancestry. Based on previous theoretical analysis and simulation
results, a nominal p value of 7 3 106 yielded a genome-wide
type I error of 0.05.32We chose not to perform admixturemapping
in the HA sample because we expect such an analysis is severelyThe Amunderpowered as a result of the lack of availability of an appro-
priate Native American reference panel (which impacts estimation
accuracy) and the smaller HA sample size (compared to the AA
sample).Conditional Analysis under Admixture Mapping
Peaks
Genetic regions showing significant association with local
ancestry tend to be broad because of the recent admixing history
in AAs. To refine these admixture mapping regions and in an effort
to reveal genes or variants that contribute to population-level trait
differences, we performed conditional analyses with all typed and
imputed SNPs in each region. We reason that variants that
‘‘explain’’ an admixture mapping peak should meet two criteria.
First, these variants should show suggestive association with the
trait conditioning on the genome-wide ancestry; and second,
these variants should substantially reduce the local ancestry-trait
association. To test the first criterion, we required the variants to
have GWAS p < 105. In genes where multiple rare variants
(defined by an allele frequency of less than 1% in AAs) show asso-
ciation with blood lipids, we also evaluated gene-based association
by using either dosage (sum of rare alleles) or an indicator defined
as dosage> 0. To assess the second criterion, we used a joint regres-
sion model that includes both local ancestry and SNP genotype in
addition to all covariates adjusted in the GWAS and required that
the p value for local ancestry to be attenuated (i.e., less significant)
by at least 100-fold compared to that in the model without the
SNP genotype. In regions where multiple SNPs or genes meet
both criteria, we performed a step-wise regression to nominate a
set of SNPs that may jointly explain the local-ancestry association.Results
Genome-wide Association Analysis
Genotype association analyses in AAs identified seven,
five, and four loci significantly associated with HDL,
LDL, and TG, respectively (Table 1 and Figure S1). For
HDL, these included CD36 (MIM 173510), PPP1R3B
(MIM 610541), LPL (MIM 609708), CETP (MIM 118470),
LOC55908, the APOA/APOC gene cluster (APOA1,
APOC3, APOA4, APOA5 [MIM 107680, MIM 107720,
MIM 107690, MIM 606368]), and an intergenic locus on
21q22; for LDL, PCSK9 (MIM 607786), APOB (MIM
107730), ABCG8 (MIM 605460), APOE (MIM 107741),
and LDLR (MIM 606945); and for TG, LPL, APOA/APOC,
APOC1 (MIM 107710), and GCKR (MIM 600842). The
inflation factor for genomic control in AAs was 1.061,
1.057, and 1.046 for HDL, LDL, and TG, respectively, indi-
cating adequate adjustment of population stratification.
With the exception of CD36 and the locus on 21q22, all
other loci are in proximity to previously implicated regions
in GWASs in Europeans.11 CD36 is a scavenger receptor
that binds long-chain fatty acids and lipoproteins; genetic
variants in CD36 have been associated with protection
from various components of the metabolic syndrome
(MetS) in AAs,33,34 and CD36-deficient individuals have
been observed to have higher HDL compared to con-
trols.35 Recently, association between a nonsynonymouserican Journal of Human Genetics 92, 904–916, June 6, 2013 907
Table 1. Loci Associated with Lipids Traits in WHI AAs
Chr
Index SNP






Gene MIM Betab p Value Trait
Genotype Association
1 rs17111684 55398136 A/G 0.120 PCSK9 607786 9.01 2.40 3 1017 LDL
2 rs12713956 21095010 G/A 0.183 APOB 107730 4.86 3.74 3 1008 LDL
2 rs4665972c 27451601 T/C 0.123 GCKR 600842 0.065 1.05 3 1008 TG
2 rs4245791 43927935 G/A 0.143 ABCG8 605460 5.97 1.24 3 1009 LDL
7 rs2366858 80178558 C/A 0.173 CD36 173510 0.0325 5.59 3 1010 HDL
8 rs1461729 9224652 T/C 0.116 PPP1R3B 610541 0.0355 7.39 3 1009 HDL
8 rs326 19863719 T/C 0.469 LPL 609708 0.0221 1.23 3 1008 HDL
8 rs326 19863719 T/C 0.469 LPL 609708 0.0410 1.02 3 1008 TG
11 rs6589566 116157633 C/T 0.0176 APOA/APOC 107680, 107720,
107690, 606368
0.2066 4.99 3 1014 TG
11 chr11: 116,799,496c 116304706 C/A 0.0016 APOA/APOC 107680, 107720,
107690, 606368
0.409 1.08 3 1012 HDL
16 rs247617 55548217 A/C 0.262 CETP 118470 0.0619 1.48 3 1044 HDL
19 rs17249141c 11061008 T/C 0.0126 LDLR 606945 32.93 2.43 3 1017 LDL
19 rs12979813 11203703 T/C 0.495 LOC55908 NA 0.0235 1.99 3 1009 HDL
19 rs1160985 50095252 C/T 0.365 APOE 107741 6.772 1.87 3 1021 LDL
19 rs12721054 50114427 G/A 0.1137 APOC1 107710 0.101 2.86 3 1019 TG
21 rs13046373 30982361 C/T 0.391 0.0226 2.26 3 1008 HDL
Admixture Mapping
9 rs10818782 98.5–101.3 Mb 0.0508 5.57 3 1007 HDL
11 rs11217785 118.6–122.1 Mb UBASH3B 609201 0.0526 2.82 3 1007 HDL
1 rs1889209 54.8–55.5 Mb PCSK9 607786 8.50 2.11 3 1006 LDL
n ¼ 7,917; 7,861; and 7,918 for HDL, LDL, and TG, respectively.
aSNPs with the lowest p value at a locus.
bFor genotype association, the direction of the regression coefficient represents the effect of each extra minor allele. For admixture mapping, the direction of the
regression coefficient represents the effect of an additional African-derived allele.
cLoci where no genotyped SNP reaches genome-wide significance (5 3 108) but at least one genotyped SNP reaches a p < 106 and at least one imputed SNP
reaches p < 5 3 108 (see Methods).SNP in CD36 (rs3211938, p.Tyr325Ter) and HDL was re-
ported in a meta-analysis in CARe.12 The same SNP
achieved a p < 7 3 109 in WHI and p < 1.45 3 1019 in
the meta-analysis that included AA participants in WHI
and CARe. The HDL-increasing allele (G) occurs at a fre-
quency of 0.28 in YRI and is essentially absent in Euro-
peans and East Asians. At 21q22, two SNPs reached
genome-wide significance in WHI AAs for HDL. This
region has not been previously implicated in lipid genetics
and was not replicated in CARe (meta p ¼ 4.10 3 106);
therefore, we did not pursue this locus further in this study.
In the WHI HA cohort, APOA/APOC and CETP reached
genome-wide significant association with HDL and
GCKR, LPL, and APOA/APOCwere found significantly asso-
ciated with TG. The number of HA participants is much
lower compared to AA participants in WHI; therefore, we
expect, a priori, that the power of GWAS is much lower
in HAs (Table 2 and Figure S2).908 The American Journal of Human Genetics 92, 904–916, June 6, 2Genetic Variants Associated with Lipid Traits Overlap
across Ethnicities and Have Correlated Allelic Effects
Previous studies of traits such as lipids, height, BMI, and
coronary heart disease have found that genetic risk factors
identified in populations of European descent often show
consistent direction of effect in non-European popula-
tions.3 In WHI, a majority of lipid loci reaching the
genome-wide significance level in AAs and all loci found
in HAs overlapped with loci discovered in European popu-
lations.11 Furthermore, we observed a strong enrichment
of small p values in the WHI cohorts among those SNPs
showing significance or suggestive evidence of association
in the European GWAS (p < 105) (Figure 1); as a com-
parison, the p value distribution for all SNPs appears
roughly uniform (Figure S3). This suggests that, with a
sufficient sample size, a large fraction of loci influencing
lipid traits in Europeans would probably reach statistical
significance in AAs and HAs.013
Table 2. Genome-wide Significant Regions in WHI HAs
Chr
Index SNP in






Gene MIM Betab p Value Trait
2 rs780094 27594741 C/T 0.358 GCKR 600842 0.0688 7.35 3 1009 TG
8 rs17410962 19892360 G/A 0.112 LPL 609708 0.1064 7.35 3 1009 TG
11 rs964184 116154127 G/C 0.248 APOA/APOC 107680, 107720,
107690, 606368
0.0459 2.81 3 1012 HDL
11 rs964184 116154127 G/C 0.248 APOA/APOC 107680, 107720,
107690, 606368
0.1567 3.66 3 1033 TG
16 rs247617 55548217 C/A 0.298 CETP 118470 0.0509 3.48 3 1016 HDL
n ¼ 3,506; 3,425; and 3,506 for HDL, LDL, and TG, respectively.
aSNPs with the lowest p value at a locus.
bThe direction of the regression coefficient represents the effect of each extra minor allele.Although previous studies have focused on consistency
of the direction of genetic effects between populations, it
is desirable to assess whether the risk variants have genetic
effects of similar magnitude because this quantity plays an
important role in individual disease risk prediction.
Furthermore, the correlation in allelic effects is a more
informative test because it also considers the strength of
correlation. A caveat in this analysis is that, in order to
avoid bias resulting from regression to the mean (or
winner’s curse), the effects should be estimated from a
sample that is independent of the sample used to select
the risk variants. Therefore, we defined lipid-associated
SNPs based on the results from the largest European
GWAS to date11 and compared the estimated genetic
effects per allele, or allelic effect, in WHI AAs and HAs.
We examined SNPs with p % 105 in Europeans for
HDL, LDL, and TG, respectively. For HDL, 992 SNPs
were considered and the correlation of the estimated
allelic effects in AAs and HAs was 0.498; for LDL, 786
SNPs were considered and the correlation was 0.429; for
TG, 810 SNPs were considered and the correlation was
0.602 (Figures 2A–2C). As a negative control, we repeated
this analysis on SNPs with p values greater than 0.01 in
Europeans. As expected, estimated allelic effects in AAs
and HAs were essentially uncorrelated (0.0113, 0.00241,
and 0.00519 for HDL, LDL, and TG, respectively). Because
some SNPs included in this analysis may be in LD, the
observed correlation between AAs and HAs may be overes-
timated. To eliminate this possibility, Figure 2D displays
the estimated genetic effects in HAs versus AAs for 92
index SNPs from distinct loci implicated in the European
GWAS for HDL, LDL, and TG. The Pearson correlation
between the estimated effects was 0.69 (p ¼ 1.11 3
1014), despite the fact that only 34 and 40 of the 92
SNPs had nominal p values less than 0.05 in AAs and
HAs, respectively. These results suggest that the degree of
overlap in risk loci between populations exceeds the set
of SNPs that replicate on the basis of a predefined p value
or significance threshold; therefore, combining associa-
tion evidence across populations is likely to increase the
overall efficiency of the ability to identify new trait loci.The AmQuantifying ‘‘Overlapping Heritability’’
Wenext asked whether loci associated in European popula-
tions contribute substantially to the genetic architecture of
lipid traits in AAs, in the sense of phenotypic variance
explained. The approachwe developed, termed population
overlap in genetic architecture (POGA), is based on an
extension of the mixed effects model of a polygenic trait,
introduced by Yang and Visscher.29 The rationale of
POGA is intuitive: if the ‘‘important’’ risk loci overlap
between populations, thenwe expect that the loci showing
the strongest evidence of association in one populationwill
account for a substantial proportion of the phenotypic
variation in another population. This approachhas two fea-
tures. First it makes use of the complete list of p values from
a reference GWAS instead of just the top SNPs; and second,
this method defines ‘‘overlap’’ more broadly to accommo-
date allelic heterogeneity and unknown LD patterns.
Figure 3 displays the proportion of phenotypic variance
in AAs explained by Gswhen the markers in s expand from
regions that met genome-wide significance levels in
Europeans to the entire genome, and will be referred to
as a POGA plot. The entire genome explains 28.5%,
30.5%, and 18.8% of the additive variance for HDL, LDL,
and TG, respectively, of which nearly one-third can be
attributed to the top 1% of the genome showing strongest
evidence of association in Europeans and more than half
can be attributed to the top 10% of the genome. The excess
variance explained by the top regions is statistically signif-
icant in the sense that the 95% confidence intervals (with
the standard error estimated by GCTA) do not include the
expected values under the null model. In HAs, too,
genomic regions showing association in Europeans ac-
count for disproportionate phenotypic variance, although
the uncertainties associated with the estimates are greater
because of the smaller sample size (Figure S5). In contrast,
when we divided the genomic regions according to a
permuted list of p values, the proportion of variance
increased roughly linearly as a proportion of the genome
included; not a single point significantly deviated from
the expectation under the null model in the POGA plot









































































Figure 1. Enrichment for Small p Values
among SNPs that Are Significantly or Sug-
gestively Associated in European GWASs
(A and B) High-density lipoprotein (HDL)
cholesterol in African Americans (AAs) (A)
and in Hispanic Americans (HAs) (B).
(C and D) Low-density lipoprotein (LDL)
cholesterol in AAs (C) and in HAs (D).
(E and F) Triglycerides (TG) in AAs (E) and
in HAs (F).Ancestry Association and Admixture Mapping in AAs
We next investigated factors that underlie ethnic differ-
ences in lipid levels. Adjusting for the same set of covari-
ates as used in the AA GWAS, genome-wide African
ancestry was associated with increased HDL (b ¼ 0.10,
p ¼ 4.26 3 107) and decreased TG (b ¼ 0.33, p <
1016) and was not significantly associated with LDL
(p¼ 0.178). This pattern is consistent with a previous anal-
ysis of an independent AA cohort in the Family Blood
Pressure Program.36,37 The phenotypic variance attributed
to genome-wide ancestry is very low: less than 0.3% for
HDL and less than 1% for TG. Comparing HAs and AAs
in WHI, HAs have significantly lower HDL (b ¼ 0.10,
p < 2 3 1016), lower LDL (b ¼ 3.56, p ¼ 5.08 3 105),
and higher TG (b ¼ 0.37, p < 2 3 1016).
Admixture mapping is an effective approach for identi-
fying loci with strong effects and disparate allele fre-
quencies between ancestral populations. Because the
recent admixing history induces strong correlation in
admixture mapping test statistics, we adopted a genome-910 The American Journal of Human Genetics 92, 904–916, June 6, 2013wide significance threshold of 7 3
106.32 In the genome-wide admix-
ture scan, local African ancestry at
9q22 (p ¼ 2.82 3 107) and at
11q23 (p ¼ 5.57 3 107) was associ-
ated with increased HDL (Table 1,
Figure S6). Together, the ancestry at
these two loci explains 0.6% of varia-
tion in HDL, and genome-wide
ancestry was no longer significantly
associated with the trait upon adjust-
ing for local ancestry at the two loci.
At 1p32, local African ancestry was
associated with decreased LDL (p ¼
2.11 3 106), explaining <0.3% of
phenotypic variation. Somewhat sur-
prisingly, no locus reached the
genome-wide significance level for
TG, despite the strong correlation
between the genome-wide African
ancestry and TG.
Association between local ancestry
and a trait can arise because the
region harbors population-specific
risk variants or because it harbors
risk variants shared among popula-tions that occur at disparate allele frequencies. Thus,
regions showing local ancestry association are excellent
candidates for identifying the genetic basis that underlies
trait differences between ethnicities. Below we describe
further fine-scale characterization of each admixture-
mapping peak. These analyses aim to identify genes or
variants that are associated with lipids and explain the
local ancestry-trait association. We note a caveat that,
because admixture generates extensive linkage disequilib-
rium, these markers may simply be in LD with the true
causal variants.
Admixture Association with LDL at 1q32
In the region of the 1q32 admixture signal for LDL (UCSC
Genome Browser hg18: 54.8–55.5 Mb), genotype associa-
tion analyses revealed three low-frequency nonsynony-
mous variants in PCSK9 associated with decreased LDL
(rs28362286 [p.Cys679Ter], rs28362263 [p.Ala443Thr],
and rs28362261 [p.Asn425Ser]); the first two variants
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Genetic Effects of Candidate
Lipid Variants Are Correlated between
AfricanAmericansandHispanicAmericans
(A–C) SNPs are those with p < 105 in a
European GWAS. The x axis represents the
estimated allelic effects in African Ameri-
cans (AAs) and the y axis represents the esti-
mated allelic effects of the corresponding
SNPs in Hispanic Americans (HAs).
(A) High-density lipoprotein (HDL)
cholesterol.
(B) Low-density lipoprotein (LDL)
cholesterol.
(C) Triglycerides (TG).
(D) Genetic effects of 92 SNPs represent-
ing independent loci; SNPs are the best
surrogate index SNPs on Affy 6.0 arrays
defined by Telosvich et al.11 The estimated
allelic effects in (D) are in the unit of
standard deviation of the phenotype.cohort,38 and the third was validated in CARe (meta-
analysis p ¼ 1.43 3 1010). Conditioning on the dosage
or carrier status of these three variants substantially
reduced the local ancestry association (p ¼ 1.15 3 102).
Curiously, we note that a nonsynonymous variant in
PCSK9, rs505151 (p.Gly670Glu), was associated with
LDL, but the allelic effect was opposite to the local ancestry
effect. The minor allele (G) at this SNP was associated with
higher LDL (p ¼ 1.09 3 106 in WHI, 4.31 3 1009 in
CARe, and 2.42 3 1012 in Europeans11); this allele occurs
in YRI at a frequency of 0.336 but at a much lower fre-
quency of 0.031 in Europeans. Indeed, a joint analysis
that included local ancestry and rs505151 showed stronger
LDL association with both variables (Table S2).
Admixture Association with HDL at 9q22
Local African ancestry at 9q22 (UCSC Genome Browser
hg18: 98.5–101.4 Mb) was associated with increased
HDL. From a biological standpoint, the nearest gene with
a plausible role in lipid metabolism is CORO2A (MIM
602159), which encodes coronin 2A. Coronin 2A
(CORO2A) is a nuclear receptor corepressor (NCoR) ex-
change factor that interacts with cholesterol-sensing liver
X receptor to derepress inflammatory genes in macro-
phages.39,40 The peak local ancestry association is 5 Mb
away from ABCA1 (MIM 600046), a known HDL locus
identified in Europeans. The ancestry association signal
vanished upon conditioning on three SNPs: rs751800 inThe American Journal of HumaCORO2A, rs1537960 in GABBR2
(MIM 607340), and rs4149310 in
ABCA1 (Table S3). At rs1537960 and
rs751800, the HDL-decreasing alleles
are essentially absent in YRI, whereas
the HDL-decreasing allele at
rs4149310 occurs in both CEU and
YRI but at a much higher frequency
in CEU. Intriguingly, previous tran-
scriptomic studies have identifiedrs751800, a SNP in the 30 UTR of CORO2A, as a cis-eQTL
in monocytes;41 based on data generated from the
ENCODE project, this SNP is categorized as likely to affect
transcription factor binding (category 1b in RegulomeDB
v.1.0).42 On the other hand, rs751800 was only weakly
associated with HDL in the CARe cohort (p ¼ 0.05) and
showed no association in Europeans.11 We note that
rs4149310 also shows suggestive association in European
populations (p ¼ 8.46 3 106); in contrast, the ABCA1
SNP with the strongest HDL association in Europeans,
rs1883025, had similar frequencies in YRI and CEU and
was not significantly associated with HDL in AAs (p ¼
0.215). Thus, rs1883025 cannot explain the HDL-ancestry
association. In summary, the ancestry-HDL association on
9q22 can be attributed to variants in CORO2A, GABBR2,
and ABCA1. Although ABCA1 appears to influence HDL
in both Europeans and AAs, the risk variants are either
distinct in the two populations or have very different allele
frequencies.
Admixture Association with HDL at 11q23
Local African ancestry at chromosomal region 11q23
(UCSC Genome Browser hg18: 118.6–122.1 Mb) was also
associated with increased HDL. The region is flanked at
either end by two HDL loci identified in Europeans,
UBASH3B (MIM 609201) and the APOA/APOC gene cluster.
At the APOA/APOC locus, 13 SNPs were associated with
HDL (p < 5 3 108) in WHI AAs. The minor alleles weren Genetics 92, 904–916, June 6, 2013 911






























Figure 3. Overlap in Genetic Architecture in AAs
Genomic regions are ranked by the SNP with the strongest associ-
ation evidence in a European GWAS. Proportions of the pheno-
typic variance explained in AAs (y axis) by the top x% of the
genome (x axis) are estimated with a mixed effect model. Red
points indicates the 95% confidence interval excludes the
912 The American Journal of Human Genetics 92, 904–916, June 6, 2each associated with decreased HDL and are all very rare
(<1% in AAs). Collectively, the number of rare variants car-
ried by WHI AA individuals was positively correlated with
African ancestry (p ¼ 0.02) and strongly correlated with
HDL (p ¼ 6.78 3 1014). We performed conditional anal-
ysis of the local-ancestry-HDL association, adjusting for
either single markers, combined dosage across all markers,
or a 0/1 variable indicating whether an individual harbors
any of the rare variants, but none of these variables ex-
plained the ancestry peak (Table S4). At UBASH3B, the
most significant SNP in Europeans (rs7115089) and the
SNP showing the strongest association in AAs (rs7107934
[p ¼ 2.49 3 107]), both occur at similar frequencies in
YRI and CEU and thus cannot explain the local ancestry as-
sociation. No other variants were found in the 2Mb region
around UBASH3B that could explain the HDL admixture
association signal. Because the local ancestry association
at 11q23 cannot be attributed to variants in APOA/APOC
or UBASH3B, the region probably harbors unrecognized
HDL-influencing loci. A plausible candidate is ABCG4
(MIM 607784), which has been shown to promote choles-
terol efflux to HDL-like particles.43,44 However, single
marker association analysis in ABCG4 did not identify sig-
nificant genotype-HDL association.Discussion
In this study, we have demonstrated a substantial overlap
in genes that contribute to the variation in plasma lipid
levels among human populations. At the same time, sub-
stantial allelic heterogeneity has been observed within
the shared loci, which contributes to the ethnic variation
in lipid levels.
A Shared Genetic Basis of Lipid Phenotypes among
Human Populations
Previous studies have found that variants associated with
lipid traits in Europeans can be ‘‘replicated’’ in non-Euro-
pean populations by using criteria of relaxed statistical
stringency and consistent direction of genetic effects.3,11
By using several approaches, we demonstrate evidence
for even greater shared genetic components beyond the
known replicated loci. First, we find a strong enrichment
of small p values, in both AAs and HAs, among SNPs that
show suggestive evidence of association in Europeans
(p < 105) (Figure 1). With an increased sample size, the
fraction of variants that can be replicated in non-European
populations is likely to increase. Second, despite someexpected value (magenta line) under the null model that x%
randomly selected genome explains h2x% of phenotypic variance,
where h2 is the variance explained by the entire genome. When
the null cannot be excluded, the point estimates are drawn with
gray points.
(A) High-density lipoprotein (HDL) cholesterol.
(B) Low-density lipoprotein (LDL) cholesterol.
(C) Triglycerides (TG).
013
well-established examples in which a genetic variant con-
fers striking population-specific risk,45,46 the estimated
genetic effects in AAs and HAs, at loci chosen based on
the association evidence in Europeans, show strong corre-
lations in both direction and magnitude (Figure 2). This is
even more striking considering the moderate sample sizes
of AAs and HAs; thus the interethnic correlation in SNP
effects will probably be strengthened with larger sample
size and reduced sampling errors. Finally, POGA plots
demonstrate that the portion of the human genome that
contributes importantly to lipid variation in Europeans
also contributes substantially to phenotypic variation in
non-Europeans: for the majority of lipid traits we exam-
ined in AAs and HAs, more than half of the additive
phenotypic variance explained by the entire genome can
be attributed to the 10% of the genome showing the stron-
gest evidence of association in Europeans (Figures 3 and
S5). This last approach is particularly useful because it
defines an overlapping genetic architecture more broadly
by taking into account the possibility that, although a
locus influences the trait in multiple populations, the pre-
cise variants may not be identical. Furthermore, a variant
discovered in a GWAS may simply be a tagging SNP for a
functional variant; hence, even when a causal variant is
shared between populations, association with the tagging
SNP may not replicate across populations because of
different LD patterns. Estimating the proportion of pheno-
typic variation that is explained by a part of the genome
accommodates both true allelic heterogeneity and popula-
tion-specific LD patterns and has an intuitive inter-
pretation as the contribution by a set of candidate loci to
phenotypic variance. Again, the degree of overlap in
genetic basis represents a lower bound because of the
limited sample sizes.
Genetic Factors that Underlie Lipid Trait Differences
between Populations
Although the distribution of plasma-lipid concentration
overlaps considerably between populations, these traits
also vary between populations. Because shared ancestry
can confound genetic and nongenetic risk factors, it is
difficult to quantify the genetic and nongenetic contribu-
tion to population differences in traits such as lipid levels.
However, genetic association and admixture mapping ana-
lyses identified a number of genetic factors that underlie
the ethnic differences. Furthermore, these examples illus-
trate that both common and rare variants can contribute
to population differences. As expected, rare variants that
contribute to population differences tend to be population
specific, exemplified by multiple African-specific variants
in PCSK9 (associated with LDL) and in APOA/APOC
(associated with HDL). However, we also identified com-
mon variants that underlie population differences: the
African-specific CD36 variant, Tyr325Ter, has a frequency
of 0.28 in YRI; the HDL-increasing allele at rs4149310 in
ABCA1 has a frequency of 0.75 and 0.14 in YRI and CEU,
respectively, and explains a large proportion of theThe Amancestry association at 9q22 with HDL (Table S2). It is
also interesting to note that PCSK9, APOA/APOC, and
ABCA1 all play a role in lipid genetics in both Europeans
and AAs, yet the precise alleles within each locus differ
between the populations. This supports a view that lipid
loci are largely shared among populations, but the allelic
structure within a locus has been shaped by population
history and thus can exhibit considerable heterogeneity.
The presence of allelic heterogeneity has also been demon-
strated in a recent transethnic study of lipid trait via the
Metabochip.47
Admixture mapping has successfully detected loci that
contribute to phenotypic diversity between populations.
In most admixture mapping examples, where the genetic
factors that give rise to the ancestry association are known,
the ancestry-phenotype association can be largely attrib-
uted to a single variant with disparate allele frequencies
between populations. Examples include SLC24A5 (MIM
609802) for skin pigmentation, DARC (MIM 613665) null
allele for white blood cells, and APOL1 (MIM 603743) for
kidney diseases; the striking genetic differentiation at the
implicated loci signifies selective sweep.48–50 In contrast,
of the three loci showing ancestry-trait association for lipid
levels (1p32, 9q22, and 11q23), none could be attributed to
single common variants. Instead, two or more variants
explain the ancestry association in an additive fashion in
each region. Furthermore, in at least one instance
(PCSK9), we find African-specific coding variants that are
associated with either increased or decreased LDL. Our
interpretation of these observations is that the evolu-
tionary dynamics of lipid traits in humans are influenced
by a combination of forces and are in contrast to the strong
directional adaptation that diversifies, for example, skin
pigmentation. Rather, the many low-frequency coding
variants may have been subjected to weak purifying selec-
tion,51 whereas the more common variants may have been
driven to disparate population allele frequencies by other
mechanisms, including balancing selection and random
drift.52
Implication for Future GWASs
Racial and ethnic minorities constitute a growing propor-
tion of the US population and suffer disproportionately
higher rates of CVD.53 The abundance of population-
specific variants that underlie lipid traits highlights the
importance of including individuals of diverse ethnic back-
ground in future GWASs. At the same time, the identi-
fication of a large fraction of ethnically shared trait loci
suggests that further insights into the genetic mechanisms
that underlie lipid traits can be gained by continued study
of multiple ethnicities simultaneously. Based on published
GWASs that focus on populations of European decent, a
majority of complex traits and diseases are influenced by
a large number of loci, each conferring a modest risk.
Studies with sample size exceeding 100,000 are nonethe-
less underpowered, as indicated by the substantial fraction
of ‘‘missing heritability.’’54 Thus, the scarcity of cohortserican Journal of Human Genetics 92, 904–916, June 6, 2013 913
that represent AAs, HAs, and other minority populations
poses a challenge for understanding the genetic basis of
complex traits in these populations. Take coronary heart
disease (CAD) as an example: the CARDIoGRAM GWAS
cohort numbered 82,000 Europeans,55 compared to the
largest published AA cohort of 8,000.56 Moreover, an
increasing proportion of the world’s populations do not
fall into conventional ethnic categories (e.g. individuals
with mixed African and South Asian ancestry). In contrast
to studying each ethnic population separately, a multi-
ethnic approach that integrates evidence across popula-
tions will probably be more efficient, both for gene dis-
covery and for individual risk prediction. One analytic
approach has been proposed and takes the form of a ‘‘trans-
ethnic meta-analysis;’’ it is desirable to extend this
approach to accommodate allelic heterogeneity and differ-
ential LD patterns.57,58 The ability to harness information
across multiple populations will provide a more complete
portrait of the genetic bases that underlie complex traits
in human species, which will in turn allow all people to
benefit from the new paradigm of personalized medicine.Supplemental Data
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